A phase I trial of an initial version of denileukin diftitox (DAB486IL-2) was conducted in patients with CD25 expressing hematological malignancies with demonstration of safety and tolerability and a ORR of 17% in CTCL patients, including 1 CR (30). The gene discussed is IL2RA; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.